Stockwinners Market Radar for May 11, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:03 EDT Zepp Health receives noncompliance letter from Nasdaq - Zepp Health announced that it has received a letter from the NYSE dated April 30, notifying Zepp that it is below compliance standards due to the trading price of Zepp's American depositary shares. Pursuant to Section 802.01C of the NYSE's Listed Company Manual, a company will be considered to be below compliance standards if the average closing price of its security as reported on the consolidated tape is less than $1.00 over a consecutive 30 trading-day period. The company has six months following receipt of the notice to regain compliance with the minimum share price requirement. The company can regain compliance at any time during the cure period if on the last trading day of any calendar month during the cure period the company has a closing share price of at least $1.00 per ADS and an average closing share price of at least $1.00 per ADS over the 30 trading-day period ending on the last trading day of that month. In the event that at the expiration of the six-month cure period, both a $1.00 per ADS closing share price on the last trading day of the cure period and a $1.00 per ADS average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. Zepp Health has advised the NYSE of its intention to cure the deficiency within the applicable cure period and is considering all available options in this regard, which may include, if necessary, effecting a reverse share split, subject to board and shareholder approval.

16:31 EDT Beacon announces $225M accelerated share repurchase agreement - Beacon announced that it has entered into an accelerated share repurchase agreement, or ASR, with Citibank to repurchase $225M of Beacon's common stock. "Creating shareholder value is central to today's announcement to continue share repurchases under our previously announced and authorized program," said Julian Francis, CEO of Beacon. "We continue to pursue our balanced capital allocation plan investing in growth and returns to shareholders. Our Ambition 2025 plan has demonstrated our ability to do both and, at the same time, deliver on margin improvement and cash flow. This ASR further emphasizes our confidence in the resiliency of our business model and our team's strong execution."

16:31 EDT Newegg Commerce receives Nasdaq notification over bid requirements - On May 8, 2024, Newegg Commerce received a letter from the Listing Qualifications Department of The Nasdaq Capital Market notifying the company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the company's common shares was below the minimum of $1.00 per share for a period of 30 consecutive business days. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The notification has no immediate effect on the listing of the company's common shares, which will continue to trade uninterrupted on Nasdaq under the ticker "NEGG." Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the company has a compliance period of 180 calendar days, or until November 4, 2024, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the company's common shares is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide the company a written confirmation of compliance and the matter will be closed. In the event the company does not regain compliance with the minimum bid price requirement by November 4, 2024, the company may be eligible for an additional 180-calendar-day grace period.

16:15 EDT Chimera announces 1-for-3 reverse stock split - Chimera Investment Corporation announced that its Board of Directors has unanimously approved a reverse stock split of the Company's common stock at a ratio of 1-for-3. The reverse stock split is expected to take effect following the close of business on May 21, 2024 (the "Effective Time"). Accordingly, at the Effective Time, every three issued and outstanding shares of the Company's common stock will be converted into one share of the Company's common stock. The Company's common stock is expected to begin trading on the New York Stock Exchange on a post-reverse stock split basis beginning on May 22, 2024, under a new CUSIP number: 16934Q 802.

15:20 EDT Xponential Fitness trading resumes

14:59 EDT SEC charges Fat Brands, executives with defrauding investors - The Securities and Exchange Commission announced that it filed fraud charges against FAT Brands Inc., its founder, former CEO, and current Chairman, Andrew Wiederhorn, and its former CFOs, Ron Roe and Rebecca Hershinger concerning FAT's disclosures about related person transactions with Wiederhorn and his family. According to the SEC's complaint, FAT owns restaurant brands, including Fatburger, Johnny Rockets, and Twin Peaks. The complaint alleges that, from October 2017 through March 2021, Wiederhorn used almost $27 million of FAT's cash on his personal expenses, including private jets, first-class airfare, luxury vacations, his rent and mortgage payments, shopping, and jewelry. Wiederhorn, with Roe's assistance, allegedly engaged in deceptive acts and made false and misleading statements to make it appear that the millions of dollars of FAT's money he was spending on himself and on his family each year were company loans to FAT's affiliate, Fog Cutter Capital Group, Inc. ("FCCG"), another company Wiederhorn controlled, for its business expenses. According to the complaint, Wiederhorn used his control over FCCG to take-in the form a personal loan that he wrote off at his sole discretion and never repaid-the money that FCCG was receiving from FAT and spend it on himself. The complaint further alleges that Wiederhorn misled FAT's board of directors and FAT's auditors, leading them to believe that FAT's loans to FCCG were being used solely for FCCG's business expenses and pre-existing liabilities. The SEC alleges that Wiederhorn's fraudulent scheme stripped FAT of approximately 40 percent of its revenue, often leaving the Company with insufficient cash to pay its own bills. Wiederhorn allegedly instructed his son to wire over $9 million into FAT, concealing that Wiederhorn used millions of FAT's funds for his own personal spending and that FAT was otherwise unable to pay its own bills. In addition, the complaint alleges that both the FAT funds transferred to FCCG and used for Wiederhorn's personal expenses, as well as the wires from his son to FAT, were reportable related person transactions that required disclosure, and that Wiederhorn, Roe, and Hershinger fraudulently made false and misleading statements in FAT's SEC filings that all reportable related person transactions had been disclosed. Reference Link

14:43 EDT Oklo falls in first day of trading on New York Stock Exchange - Oklo (OKLO), which identifies itself as "a fast fission clean power technology and nuclear fuel recycling company," began trading on the New York Stock Exchange under the new ticker symbol "OKLO," effective at market open today, following the completion of its business combination with AltC Acquisition Corp. (ALCC). In Friday afternoon trading, Oklo shares have fallen $8.65, or 47%, to $9.58. Sam Altman, Chairman of Oklo since 2015 and former Chief Executive Officer of AltC, said, "Today is a milestone for the entire Oklo team. As one of the initial investors in the company, I've seen first-hand how Oklo has proven itself to be a clean energy leader and innovator, developing a cost-competitive go-to-market strategy, and solidifying important relationships with regulators, customers, and suppliers. There are huge growth opportunities ahead. With Jake, Caroline, and the rest of the management team at the helm, I am confident they will continue pioneering advanced fission energy solutions as a public company." Oklo added: "The company has received $306 million in gross proceeds from the transaction before taking into account expenses associated with the transaction, which is expected to be used to execute Oklo's business plan and fund the initial deployment of the company's Aurora powerhouse. Oklo stands well-positioned to drive successful long-term growth and shareholder value creation through the combination of the funding received from the transaction coupled with its unique set of strategic agreements. Key agreements include partnerships with Diamondback Energy, Inc., one of the largest independent shale-oil producers, and Centrus Energy Corp. Moreover, the recent approval of the Safety Design Strategy for the Oklo Aurora Fuel Fabrication Facility marks an important step in the U.S. Department of Energy's approval process."

13:27 EDT Rhode Island Energy, UWUA-BUW locals reach agreement on five-year contracts - Rhode Island Energy, a subsidiary of PPL Corporation, has announced it reached an agreement on new five-year contracts with the Utility Workers Union of America, AFL-CIO, Locals 310 and 310B, and Brotherhood of Utility Workers, which currently represent 526 employees. "We value each of our employees and their dedication to serving our customers and are proud of the positive partnership between our unions and company leadership. These contracts are the result of our ongoing collaborative efforts," said Greg Cornett, president of Rhode Island Energy. The agreements, which extend existing contracts and will now be in effect from May 12, 2024, through May 11, 2029, both include 3% annual wage increases each year of the contracts for all employees represented by Locals 310 and 310B.

13:02 EDT Baker Hughes reports U.S. rig count down 2 to 603 rigs - Baker Hughes reports that the U.S. rig count is down 2 from last week to 603 with oil rigs down 3 to 496, gas rigs up 1 to 103 and miscellaneous rigs unchanged at 4. The U.S. Rig Count is down 128 rigs from last year's count of 731 with oil rigs down 90, gas rigs down 38 and miscellaneous unchanged. The U.S. Offshore Rig Count is up 1 to 19, down 3 year-over-year. The Canada Rig Count is down 4 from last week to 116, with oil rigs unchanged at 60, and gas rigs down 4 to 56. The Canada Rig Count is up 22 from last year's count of 94, with oil rigs up 23, and gas rigs down 1.

12:54 EDT ContextLogic announces ticker symbol to change to 'LOGC' on May 13 - ContextLogic announced that its Class A common stock will begin trading on NASDAQ under the ticker symbol "LOGC" prior to market open on May 13, 2024. This will replace the company's current ticker symbol "WISH", which has been used since its initial public offering in December 2020. The new ticker symbol comes following the company's sale of the Wish e-commerce platform to Qube Network Pte. Ltd., a subsidiary of Qoo10 Pte. Ltd., which was completed on April 19, 2024. Because the company is not changing its name, no action by the company's shareholders is required with respect to the ticker symbol change. The company's Class A common stock will continue to be listed on NASDAQ.

12:01 EDT Orion Group rises 14.5% - Orion Group is up 14.5%, or $1.11 to $8.78.

12:00 EDT Sweetgreen rises 36.0% - Sweetgreen is up 36.0%, or $8.47 to $32.03.

12:00 EDT CS Disco falls -19.3% - CS Disco is down -19.3%, or -$1.56 to $6.51.

11:58 EDT FAT Brands Inc trading resumes

11:53 EDT FAT Brands Inc trading halted, volatility trading pause

10:33 EDT Papa John's says Q2-to-date North America comp sales down 1% - CEO Ravi Thanawala said: "Looking at our outlook for the balance of the year. For the first four weeks of the second quarter, North America comp sales were down approximately 1% and may remain under pressure in the near term as the challenging macroeconomic environment continues and consumer confidence softens. Because of this, we have chosen to update our full year guidance with a more cautious outlook. If orders remain at a similar level as the past four weeks, we anticipate 2024 North America comps to be flat to down low single digits for the full year 2024. As a reminder, we are in the early stages of our Back to Better 2.0 investments and are committed to providing updates as the year progresses. Internationally, we remain in a dynamic environment and continue to maintain a cautious outlook on international comps in 2024." Comments taken from Q1 earnings conference call yesterday.

10:01 EDT Ouster rises 28.6% - Ouster is up 28.6%, or $2.96 to $13.31.

10:00 EDT American Vanguard falls -15.9% - American Vanguard is down -15.9%, or -$2.00 to $10.63.

10:00 EDT Savers Value Village falls -17.3% - Savers Value Village is down -17.3%, or -$2.98 to $14.18.

09:48 EDT DNOW Inc. falls -12.6% - DNOW Inc. is down -12.6%, or -$1.88 to $12.99.

09:47 EDT Ouster rises 16.9% - Ouster is up 16.9%, or $1.75 to $12.10.

09:47 EDT Sweetgreen rises 29.7% - Sweetgreen is up 29.7%, or $6.99 to $30.55.

09:40 EDT CS Disco trading resumes

09:24 EDT Applied DNA Sciences regains compliance with Nasdaq minimum bid price rule - Applied DNA Sciences announced that on May 9, 2024, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously reported, the Company was notified on December 1, 2023, that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid of the Company's ordinary shares needed to be at least $1.00 for a minimum of 10 consecutive business days. The Notification Letter confirmed that the Company evidenced a closing bid price at or greater than the $1.00 per ordinary share minimum requirement for 10 consecutive business days from April 25, 2024, to May 8, 2024, and that the Company has regained compliance with the Minimum Bid Price Requirement.

09:09 EDT Winvest Acquisition announces extension of termination date - WinVest Acquisition announced that its Board of Directors has approved an extension of the period of time available to the Company to consummate an initial business combination by one month from May 17, 2024 to June 17, 2024, as permitted under the Company's Amended and Restated Certificate of Incorporation, as amended. The purpose of the extension is to provide additional time for the Company to complete an initial business combination. In connection with the extension, $55,000 will be deposited into the trust account established in connection with the Company's initial public offering pursuant to the Company's sixth drawdown upon an unsecured non-interest-bearing promissory note in the aggregate principal amount of $330,000 issued by the Company to WinVest SPAC on December 13, 2023.

09:07 EDT Q2 Holdings chairman R.H. Seale III to switch roles, Matt Flake to succeed - Q2 Holdings announced that chairman R.H. Seale III will not stand for re-election to Q2's board of directors at the end of his current term, which expires on June 11. In recognition of his role as the founder of Q2, the board has appointed Seale as chairman emeritus. Q2's CEO Matt Flake will succeed Seale as chairman of the board, effective June 11.

09:02 EDT YY Group announces entry into the Cambodian hospitality and hotel industry - YY Group announced its entry into the Cambodian hospitality and hotel industry. This expansion, which follows on the Company's recent entry into Vietnam and Malaysia, is expected to help YY Group gain market share in Cambodia. The Company estimates that the Cambodian hotel industry has the potential for over $106M in revenue by 2024.

08:56 EDT PhenixFIN board declares special dividend of $1.31 per share - On May 9, 2024 the Board of Directors declared a special dividend of $1.31 per share. This dividend is payable on June 10, 2024 to stockholders of record as of May 27, 2024.

08:43 EDT T. Rowe Price reports preliminary AUM $1.48T at April 30 - T. Rowe Price Group reported preliminary month-end assets under management of $1.48 trillion as of April 30, 2024. Preliminary net outflows for April 2024 were $7.8 billion.

08:36 EDT Global Water Resources reports results of director election - Global Water Resources announced that the nominees listed in the Proxy Statement, dated March 26, 2024, for the 2024 Annual Meeting of Stockholders were selected as Directors of the Company. As of the March 14, 2024 record date for the determination of the shareholders entitled to notice of and to vote at the meeting, 24,175,947 shares of common stock were outstanding and eligible to vote. A total of 20,682,036 shares were voted in person or by proxy at the meeting. In addition, at the Meeting, the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified. In addition, at the Meeting, approval on an advisory basis, of the compensation of the Company's named executive officers was approved. Also at the Meeting, the ratification of the amendment to the 2020 Incentive Plan to increase the total number of shares in the plan was approved.

08:26 EDT Acadian Timber announces election of directors - Acadian Timber Corp. announced that the nominees listed in the management proxy circular for the 2024 Annual Meeting of Shareholders were elected as directors of the Company.

08:17 EDT Boston Omaha announces departure of Alex Rozek as co-CEO, co-chair - Boston Omaha (BOC) announced that Alex Rozek, co-CEO and co-chair, has left the company, effective as of May 9 to pursue new entrepreneurial opportunities. Adam Peterson will continue to lead the company as chair and CEO. Although Rozek intends to pursue new entrepreneurial activities, he will continue to serve as Boston Omaha's board designee at Sky Harbour (SKYH).

08:11 EDT Azitra presents data from ATR-12 study at ASGCT - Azitra announced preclinical data from the company's platform and pipeline. The data are being presented on Friday, May 10 in two oral sessions entitled "Engineered Staphylococcus Epidermidis as a Protein Delivery System for Treating Skin Diseases" and "Staphylococcus epidermidis Strain Expressing LEKTI-D6 for Netherton Syndrome" at the American Society of Gene and Cell Therapy, or ASGCT, 2024 Annual Meeting in Baltimore, Maryland. The data in the two oral presentations today showcase the preclinical development of ATR-12 and the clinical study design of a Phase 1b study in Netherton syndrome patients. In vitro data show that LEKTI protein secreted by ATR-12 has nanomolar inhibition of a key protease that drives Netherton syndrome, kallikrein 5. Additionally, in human ex vivo Netherton syndrome models, ATR-12 supernatant reduces protease activity nearly 7-fold to levels comparable to healthy skin. Furthermore, in ex vivo human skin models, ATR-12 led to a higher amount of LEKTI delivery to the skin compared to topically applied LEKTI alone after 24 hours and resulted in deeper biodistribution of LEKTI. Application of ATR-12 in human skin cell culture reduced IL-36gamma by 92% compared to skin extracts induced to overexpress IL-36gamma. Topical application of ATR-12 to in vitro human skin treated with erlotinib reduced IL-36gamma by 69%. In studies conducted in minipigs with abraded skin, topical application of ATR-12 resulted in 11.9 ng/cm2 of LEKTI on the surface of the skin vs. 2.6 ng/cm2 in the vehicle group at day 14. ATR-12 application was safe and well-tolerated in GLP toxicology studies with minipigs. The oral presentation entitled "Staphylococcus epidermidis Strain Expressing LEKTI-D6 for Netherton Syndrome" also provides the study design for an active clinical trial of ATR-12 in Netherton syndrome patients. The Phase 1b study is a multicenter, randomized, double-blind, vehicle-controlled study in adults with Netherton syndrome. Patients will be treated twice daily with 109 CFU / g ATR-12 for 14 days. The primary objective is to assess the safety and tolerability of topical application of ATR-12, and the secondary objectives are to evaluate efficacy signals and to evaluate the skin pharmacokinetics of LEKTI. Exploratory objectives include the evaluation of pharmacodynamic parameters, including anti-LEKTI response, cytokine responses, biomarkers such as KLK5, KLK7, IL-36gamma, trypsin-like activity, and chymotrypsin-like activity.

08:11 EDT Ekso Bionics says Ekso Indego Personal to be featured on 'Health Uncensored' - Ekso Bionics Holdings announced the Ekso Indego Personal will be featured on 'Health Uncensored' hosted by Dr. Drew Pinsky. The episode is scheduled to air on the Fox Business News channel on Sunday, May 12 at 5:30 p.m. ET / 2:30 p.m. PT. Scott Davis, Chief Executive Officer of Ekso Bionics, Michael Glover, Director of Clinical Operations of Ekso Bionics, and Jim Gritton, an Ekso Indego Personal device user, will join Dr. Drew to share the user reported benefits and advanced technology of the Ekso Indego Personal, a powered exoskeleton that is designed to provide patients with mobility impairments the opportunity to walk independently. "For spinal cord injury individuals previously confined to a wheelchair, our transformative Ekso Indego Personal offers a potentially life-changing solution that can significantly improve their quality of life," says Scott Davis, Chief Executive Officer of Ekso Bionics. "Known for its ease of use, modular design, and ability to generate fast walking speeds, the Ekso Indego Personal is designed to allow patients to regain their mobility and independence in their homes and communities. We look forward to sharing stories of patients who are using our Indego device on 'Health Uncensored' with Dr. Drew."

08:08 EDT Mobile-health Network Solutions establishes subsidiary in Malasia - Mobile-health Network Solutions announced the establishment of a subsidiary in Malaysia. This strategic expansion signifies MNDR's commitment to delivering accessible and affordable healthcare services throughout Southeast Asia. The Malaysian subsidiary marks a pivotal step in the Company's growth trajectory. It positions the Company as a frontrunner in telemedicine solutions across Southeast Asia, enabling MNDR to cater to the region's evolving healthcare needs. This expansion fosters wider patient reach and brand recognition, solidifying the Company's position as a leader in the burgeoning telemedicine landscape.

08:07 EDT Ford CFO John Lawler to become vice chair, Sherry House to succeed in 2025 - Ford (F) announced senior leadership moves designed to build on significant progress against its Ford+ plan and speed profitable growth through a more resilient business. John Lawler, Ford's CFO since October 2020, will initially continue in that role while also becoming vice chair, a position in which he will lead the company in areas critical to its long-term success. Additionally, Sherry House, who most recently was CFO at electric vehicle maker Lucid Motors (LCID), is joining Ford as vice president, finance, part of a plan to succeed Lawler as CFO in early 2025. In the meantime, she will oversee financial planning and analysis as well as the finance organizations for the company's automotive businesses: Ford Blue, Ford Pro and Ford Model e. Both assignments are effective in early June. As vice chair, Lawler will focus on: The next phase of Ford's strategic development, including choices across technologies, markets, alliances and segments. All current and future global partnerships, and engagement with global leaders as vice chair, including in China, Southeast Asia and Europe, to advance policy in areas vital to Ford's strategic and commercial imperatives.

08:05 EDT Intensity Therapeutics, The Swiss Group sign collaboration agreement - Intensity Therapeutics announces that the Company executed a collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK to conduct a Phase 2 randomized, controlled trial evaluating clinical and biological effects of intratumoral INT230-6 followed by the standard of care immuno/chemotherapy vs. SOC immune/chemotherapy alone in early-stage triple-negative breast cancer in 54 patients in Switzerland and selected countries in Europe. The INVINCIBLE-4 Study is an open-label randomized two-cohort phase 2 clinical trial.

08:03 EDT Dstillery announces collaboration with Similarweb - Dstillery announced its new collaboration with Similarweb. Similarweb's trusted view of website usage across the internet is now used to help train the AI technology behind Dstillery's patented ID-free solution, the industry's only behavioral targeting solution without IDs. "Similarweb and Dstillery share an understanding of the business value of AI as we mature the technology and focus it on practical applications," said Benjamin Seror, Chief Product Officer at Similarweb. "But AI algorithms are only as good as the data they're trained on, and Similarweb Digital Data is the premium choice for understanding the digital world. We're working with Distillery to ensure businesses get the benefits of AI while respecting privacy concerns."

08:02 EDT PharmaTher announces assigned GDUFA goal data for Ketamine ANDA - PharmaTher Holdings announced receipt of an Amendment Acknowledgment Letter for its Priority Original Abbreviated New Drug Application for Ketamine from the U.S. Food and Drug Administration and assigned a Generic Drug User Fee Amendments of 2022 goal date of October 29, 2024. As announced by the Company on April 18, 2024, the receipt of a Complete Response Letter similar to the review letter FDA provided on possible deficiencies identified by Quality, as announced on February 12, 2024. There were no additional deficiencies mentioned in the CRL and AAL. The Company, demonstrating its commitment to quality and compliance, promptly completed the necessary tests and responses to address the FDA's comments and submitted them to the FDA for their review, which resulted in the GDUFA goal date of October 29, 2024. The Company will provide updates as they occur. The Company's overall goal is to solve the ketamine shortage problem in the U.S. and its ketamine to adhere to the FDA's strict manufacturing guidelines and FDA-approved prescribing label. Following the anticipated FDA approval and launch in the U.S., the Company aims to pursue international approvals to support the global demand for ketamine. The Company's long-term strategy is pursuing novel uses and delivery methods of ketamine as a potential treatment for pain, mental health, and neurological disorders.

07:57 EDT United Bankshares to acquire Piedmont Bancorp for $267M - United Bankshares and Piedmont Bancorp announced they have entered into a definitive merger agreement under which United will acquire Piedmont. The combined organization will have more than $32B in assets and a network of over 240 locations across eight states and Washington, D.C., in some of the most desirable banking markets in the nation. Piedmont, headquartered in Peachtree Corners, Georgia, has assets of approximately $2.1B and 16 locations. Pursuant to the merger agreement, United will acquire 100% of the outstanding shares of Piedmont in exchange for common shares of United. The exchange ratio will be fixed at 0.300 of United's shares for each share of Piedmont, resulting in an aggregate transaction value of approximately $267M. The merger has been approved by the boards of directors of both companies. The merger is expected to close late in the fourth quarter of 2024 or early in the first quarter of 2025, subject to the satisfaction of customary closing conditions, including approval by the shareholders of Piedmont and the receipt of required regulatory approvals which at the Federal level include the approval of the Federal Reserve. Piedmont will merge into United, and The Piedmont Bank will merge into United Bank, with United and United Bank being the surviving entities.

07:46 EDT Moderna says FDA does not expect to complete mRNA-1345 BLA review by May 12 - Moderna announced it has been notified by the U.S. Food and Drug Administration that due to administrative constraints, the agency does not expect to complete its review of the Biologics License Application for mRNA-1345, Moderna's investigational respiratory syncytial virus vaccine, by the previously communicated Prescription Drug User Fee Act date of May 12, 2024. The FDA has informed Moderna that it is working to conclude the review by the end of May 2024. The FDA has not informed Moderna of any issues related to vaccine safety, efficacy or quality that would prevent the approval of mRNA-1345. Moderna remains on track for mRNA-1345 to be reviewed at the CDC's Advisory Committee on Immunization Practices June 26-27, 2024, meeting, which is necessary prior to commercial launch.

07:43 EDT Pacira prices $250M aggregate principal amount of convertible senior notes - Pacira BioSciences, announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Pacira also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on May 14, 2024, subject to customary closing conditions. Pacira estimates that the net proceeds from the offering will be approximately $242.0 million, after deducting the initial purchasers' discounts and commissions and estimated offering expenses. Pacira expects to use approximately $191.4 million of the net proceeds to repurchase $200.0 million aggregate principal amount of its outstanding 0.750% Convertible Senior Notes due 2025 concurrently with the note offering in privately negotiated transactions effected through one of the initial purchasers of the notes or its affiliate, as Pacira's agent, approximately $23.2 million of the net proceeds to fund the cost of entering into the capped call transactions described below and approximately $25.0 million of the net proceeds to repurchase 837,240 shares of Pacira's common stock concurrently with the pricing of the note offering in privately negotiated transactions. Pacira intends to use the remainder of the net proceeds from the offering for general corporate purposes, including working capital, and research and development expenditures. Holders of the 2025 Notes that are repurchased in the concurrent repurchases described above may purchase shares of Pacira's common stock in the open market to unwind any hedge positions they may have with respect to the 2025 Notes. These activities may affect the trading price of Pacira common stock and the initial conversion price of the notes. The notes will be general unsecured senior obligations of Pacira and will mature on May 15, 2029, unless earlier repurchased, redeemed or converted in accordance with their terms. The notes will bear interest at a fixed rate of 2.125% per year, payable semi- annually in arrears on May 15 and November 15 of each year, beginning on November 15, 2024. Prior to the close of business on the business day immediately preceding November 15, 2028, the notes are convertible at the option of the holders only under certain conditions.

07:37 EDT Black Diamond announces approval of all resolutions at Annual, Special Meeting - Black Diamond Group announced the voting results from its annual general and special meeting of shareholders held on May 9, 2024. A total of 40,064,561 common shares, representing approximately 64.71% of Black Diamond's issued and outstanding common shares, were represented in person or by proxy at the Meeting. The following nominees were elected as directors of Black Diamond for the ensuing year: Trevor Haynes; Brian Hedgesl Robert J. Herdman; Barbara J. Kelley; Edward H. Kernaghan; Leilani Latimer; Steven Stein; Robert Wagemakers. In addition, all other resolutions presented at the Meeting were approved by Black Diamond's shareholders, including the appointment of Ernst & Young LLP, Chartered Professional Accountants, as auditors; the approval of the unallocated options under Black Diamond's share option plan; the approval of the issuance of common shares of Black Diamond from treasury pursuant to Black Diamond's restricted and performance award incentive plan; and the approval of the amended and restated shareholder protection rights plan agreement.

07:28 EDT ESGL Holdings expects cash to meet working capital, capex needs in 2024 - As of December 31, 2023, ESGL had approximately $0.4 million in total cash and equivalents compared to approximately $0.3 million at the end of 2022. Subsequent to the close of the year, ESGL secured an additional $2.5 million in a private placement of common stock in April 2024. The Company believes that its current cash, combined with anticipated cash generated from operating activities, will meet its anticipated working capital and modest capex needs in 2024.

07:21 EDT Antelope Enterprise believes livestreaming ecommerce business is sustainable - The company said, "The Company operates a livestreaming ecommerce business through its KylinCloud subsidiary. Kylin Cloud's platform strategically matches appropriate hosts and influencers to the products of consumer brand companies which results in increased sales for consumer brand companies. For the second six months and the full year 2023, KylinCloud generated primarily all of the Company's total revenue. The Company believes its livestreaming ecommerce business is sustainable since livestreaming can offer consumer brand companies a new distribution channel, a potentially large audience and creative content. In addition, it can offer shoppers better engagement, convenience, authenticity and greater information as compared to conventional shopping modes. Livestreaming ecommerce can also accelerate purchasing decisions and increase conversion rates as compared to conventional ecommerce. The Company recently announced the planning for the launch of its energy supply business to be operated via its wholly-owned subsidiary, AEHL US LLC. AEHL US has taken preliminary steps in developing this business including engaging a broker to source natural gas from natural gas providers in Texas and the procurement of electricity generators. AEHL US plans to supply power to a data center in Midland, Texas. The Company anticipates that its energy supply business will start operation in the third quarter of 2024. The Company also plans to generate revenue by securing hosting sites for cryptocurrency mining operators as it leverages anticipated cost-effective electricity costs."

07:16 EDT Century announces two presentations on CNTY-101 at ASGCT 27th Annual Meeting - Century Therapeutics announced two poster presentations at the ASGCT 27th Annual Meeting. The data presented highlights the potential of the Company's lead candidate, CNTY-101, to treat B-cell driven autoimmune diseases including SLE. Additionally, the Company presented data which further demonstrates the capabilities of its Allo-Evasion technology through new preclinical data of a CD300a agonist which can potentially inhibit natural killer (NK) cell alloreactivity. Details of the posters are: Characterization of CNTY-101, an Allogeneic Anti-CD19 iPSC-Derived NK Product, for the Treatment of B Cell-Driven Autoimmune Diseases; and Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies.

07:10 EDT Inspired Entertainment announces debut of its NBA Re-Play in Greece - Inspired Entertainment announced the debut of its NBA Re-Play Virtual Sports product exclusively in Greece with long-time partner OPAP. OPAP is the leading gaming company in Greece and one of the most renowned internationally, offering a wide range of games, including numerical lotteries, sports betting, passive lotteries, scratch cards, etc. The partnership strategically positions OPAP as the first Inspired partner to officially introduce NBA Re-Play across more than 3,000 retail venues. This way, OPAP pioneers in the market and provides an innovative virtual gaming experience to its customers across Greece.

07:06 EDT Instil Bio sees cash runway beyond 2026 - As of March 31, 2024, Instil had cash, cash equivalents, marketable securities and long-term investments of $161.5 million, which consisted of $5.5 million in cash and cash equivalents, $148.3 million in marketable securities and $7.7 million in long-term investments, compared to $175.0 million in total cash, cash equivalents, restricted cash, marketable securities and long-term investments, which consisted of $9.2 million in cash and cash equivalents, $1.5 million in restricted cash, $141.2 million marketable securities and $23.2 million in long-term investments as of December 31, 2023. Instil expects that its cash, cash equivalents, marketable securities and long-term investments as of March 31, 2024 will enable it to fund its current operating plan beyond 2026.

06:50 EDT Golden Minerals announces sale of Velardena assets for $5.5M plus VAT - Golden Minerals Company has entered into a definitive agreement to sell the primary assets comprising its Velardena Properties, located in Durango State, Mexico. On April 29, 2024, two of Golden's Mexico subsidiaries, Minera William and Minera Labri Sentered into certain asset purchase and sale agreements with a privately held Mexican company whereby Minera William and Minera Labri agreed to sell certain mining concessions, equipment, land parcels and other assets to the buyer in exchange for an aggregate purchase price of $5.5M in cash, plus Value-Added Tax. The assets being sold include the Velardena and Chicago mines, both of the Company's oxide and sulfide processing plants and related equipment. Under the terms of the sales agreements: On April 29, 2024, the buyer paid a non-refundable advance payment of $1M in cash to the Company; On May 20, 2024, the buyer shall pay $2M in cash, plus VAT, to the Company, and On July 1, 2024, the buyer shall pay $2.5M in cash, plus VAT, to the Company.

06:39 EDT Centogene Biodatabank grows to incorporate insights from over 850K patients - Centogene revealed significant growth in the CENTOGENE Biodatabank. Analysis of this patient data enables precise diagnosis of disease, identification of new genetic variants, and potential de-risking of drug development. The number of analyzed patient cases has grown by 13% to more than 850,000 patients as of December 31, 2023, compared to December 21, 2022, and the number of total unique variants has increased by 19% to over 850,000,000. This includes patients from over 120 countries, over 70% of whom are of non-European descent, underscoring the ethnic diversity of CENTOGENE's knowledgebase.

06:32 EDT Ault reports 89 Bitcoin mined in April - Ault Alliance announced that its wholly owned subsidiary, Sentinum, mined approximately 89 Bitcoin in April. Of this total, approximately 46 Bitcoin were mined at Sentinum's data center in Michigan, with the remaining approximately 43 Bitcoin having been mined using the miners hosted by Core Scientific. Ault Alliance notes that all estimates and other projections are subject to the volatility in Bitcoin market price.

06:27 EDT AngloGold Ashanti reports 2% year-on-year increase in Q1 gold production - AngloGold Ashanti reported a 2% year-on-year increase in first quarter gold production, in line with its plans and despite the previously reported impact of rains and flooding in Western Australia on gold production which contributed to a drop of about 15,000oz in production in the first quarter relative to the previous quarter. The Company reconfirmed its 2024 full-year gold production guidance and its 2024 annual gold production forecast for Obuasi in Ghana, which continues its ramp-up. "This is a good start to the year, with another strong safety result and a good overall performance from the portfolio," said CEO Alberto Calderon. "We're seeing greater consistency from most of our operations; in Brazil, both sites have shown significantly better performance, with greater production control and stability. Geita and Kibali were strong again, and Obuasi's ramp-up remains on track." AngloGold Ashanti continues to take steps to close the value gap that exists with its North American peers by improving safety, relative cost performance and cash conversion, while increasing the life of its key mines and prioritising successful development of major projects. The Company's Total Recordable Injury Frequency Rate was 1.08 injuries per million hours worked during the first quarter of 2024, compared to the most recent average of 2.66 for members of the International Council on Metals & Minerals. No fatalities were recorded at mines operated by the Company in the first three months of 2024, for the eleventh consecutive quarter. Gold production1 was 2% higher year-on-year at 581,000oz for the first quarter of 2024, compared to 572,000oz for the first quarter of 2023, driven mainly by higher recovered grades, and partly offset by lower tonnes processed. Strong improvements in gold production versus the first quarter of last year were recorded at Cuiaba and Serra Grande, where initiatives have been taken to improve overall performance, as well as at Kibali and at Geita. This increase in gold production was partly offset by lower gold production at Siguiri, where carbonaceous ore in the Bidini pit resulted in poor recoveries, and at Tropicana where severe flooding, caused by a tropical cyclone, inundated underground and open pit mining areas as well as access roads to the remote site. Both mines have since recovered to normalised gold production levels. Sunrise Dam also suffered from the heavy rainfall in Western Australia, albeit to a lesser extent than Tropicana, while gold production at Cerro Vanguardia was lower due to a planned plant stoppage. The Company provided gold production guidance for 2024 in February, which remains unchanged. Gold production is again expected to be second half weighted, with fourth quarter gold production expected to be the strongest quarter this year.

06:08 EDT Editas announces preclinical data from in vivo gene editing medicines - Editas Medicine announced the presentation of preclinical data demonstrating several in vivo capabilities towards developing transformative in vivo gene editing medicines. The Company will report these data later today in an oral presentation at Annual Meeting of the American Society of Gene and Cell Therapy, ASGCT, in Baltimore and virtually. Data highlights include: Developed and optimized an LNP specifically for in vivo gene editing with a lipid formulation that robustly transfects the ocular trabecular meshwork, Identified modifications to the guide RNA that improve in vivo editing efficiency, Developed a mouse model of myocilin-associated primary open angle glaucoma where expression of human mutant myocilin results in elevated intraocular pressure; Demonstrated efficacy with AsCas12a nuclease in vivo; Administered optimized LNP delivering AsCas12a mRNA and optimized gRNA into a POAG model resulting in a decrease in IOP at all doses tested.

06:05 EDT Rocket announces data updates from its lentiviral portfolio - Rocket Pharmaceuticals announced longer-term data updates from its lentiviral, or LV, vector hematology portfolio presented at the 27th Annual Meeting of the American Society of Gene and Cell Therapy, or ASGCT. Data updates demonstrate the continued safety and efficacy of the Phase 1/2 pivotal studies of KRESLADI, or marnetegragene autotemcel, for severe Leukocyte Adhesion Deficiency-I, or LAD-I, and RP-L102 for Fanconi Anemia, or FA, in addition to the Phase 1 study of RP-L301 for Pyruvate Kinase Deficiency, or PKD. The oral presentation includes positive, updated data from the global Phase 1/2 pivotal studies demonstrating sustained efficacy and safety of KRESLADITM from 18 to 45 months of follow-up for all nine patients with severe LAD-I. Observed 100% survival in the absence of allogeneic HSCT at least 18 months post-infusion in all nine patients; all patients enrolled at less than 12 months of age have surpassed 24 months without HSCT. All primary and secondary endpoints were met, including sustained genetic and phenotypic correction. When compared with pre-treatment history, data showed substantial decreases in the incidences of significant infections requiring hospitalization or intravenous antimicrobials, combined with evidence of resolution of LAD-I-related skin and periodontal lesions and restoration of wound repair capabilities. KRESLADITM was well-tolerated in all patients with no drug-related serious adverse events reported to date. Adverse events related to other study procedures, including busulfan conditioning, have been previously disclosed and are consistent with the safety profiles of those agents and procedures. No cases of graft failure or autologous graft-versus-host-disease were reported. Based on the positive efficacy and safety data from the global pivotal studies of KRESLADITM for severe LAD-I, the Biologics License Application was accepted for review by the FDA who has set the New Prescription Drug User Fee Act target date of June 30.

05:32 EDT Sonida Senior Living appoints Max Levy as CIO - Sonida Senior Living announced the appointment of Max Levy to the newly created role of chief investment officer, or CIO. In addition, the company also announced that Lilly Donohue will be appointed to the board.

05:13 EDT Novavax to initiate additional cost reduction program - Novavax is prepared to initiate an additional cost reduction program to reduce 2025 R&D plus SG&A expenses to below $500M, a portion of which it expects to be reimbursed by Sanofi under the agreement. This reflects a greater than $225M reduction beyond prior stated targets.